Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALVID-1
NCT04379271Phase 3Completed
- Sponsor
- Immunic Therapeutics
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of vidofludimus calcium in coronavirus disease 2019 (COVID-19), sponsored by Immunic Therapeutics. Started Jun 2020; status: completed.
02
Drugs
vidofludimus calcium
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04379271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04379271.